Park Jiyeon Joy, Arafath Syed, Kumar Samir T, Sharma Roopali, Dixit Deepali
Jiyeon Joy Park is a clinical assistant professor and oncology specialist in the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, in East Rutherford, N.J. Syed Arafath is an oncology clinical pharmacy specialist at New York-Presbyterian Weill Cornell Medical Center in Jamaica, N.Y. Samir T. Kumar is an internal medicine resident at the State University of New York's Downstate Medical Center in Brooklyn, N.Y. Roopali Sharma is a clinical associate professor and infectious disease specialist at Touro College's School of Pharmacy in New York, N.Y. Deepali Dixit is a clinical associate professor in the Ernest Mario School of Pharmacy at Rutgers and a clinical pharmacy specialist in critical care at Robert Wood Johnson University Hospital in Piscataway, N.J. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2021 Jun 1;34(6):32-39. doi: 10.1097/01.JAA.0000735760.65235.3c.
Recent development of immunotherapy has led to remarkable advancement in cancer therapy. Drugs that inhibit the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways have shown improved patient survival. However, by altering the immune response to fight cancer, a new class of adverse reactions has emerged, known as immune-related adverse events. These adverse events are due to overactivation of the immune system in almost any organ of the body, can occur at any point in a patient's treatment course, and may become life-threatening. This article describes how to promptly recognize and manage these toxicities.
免疫疗法的最新进展已使癌症治疗取得了显著进步。抑制细胞毒性T淋巴细胞相关蛋白（CTLA-4）和程序性死亡蛋白1（PD-1）免疫检查点通路的药物已显示出可提高患者生存率。然而，通过改变对抗癌症的免疫反应，一类新的不良反应出现了，即免疫相关不良事件。这些不良事件是由于身体几乎任何器官的免疫系统过度激活所致，可在患者治疗过程中的任何时间点发生，并且可能危及生命。本文介绍了如何迅速识别和处理这些毒性反应。
